A5019416771- Renal Transplantation Outcomes and Treatments
- Organ Donation and Transplantation
- Organ Transplantation Techniques and Outcomes
- Neurological Complications and Syndromes
- Polyomavirus and related diseases
- Pharmacological Effects and Toxicity Studies
- Renal and Vascular Pathologies
- Transplantation: Methods and Outcomes
- Pregnancy and Medication Impact
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Organ and Tissue Transplantation Research
- Renal Diseases and Glomerulopathies
- Pneumocystis jirovecii pneumonia detection and treatment
- Oral and gingival health research
- Peripheral Artery Disease Management
- Immune Cell Function and Interaction
- Palliative Care and End-of-Life Issues
- Adenosine and Purinergic Signaling
- Complement system in diseases
- Animal Virus Infections Studies
- Parvovirus B19 Infection Studies
- Cardiac, Anesthesia and Surgical Outcomes
- HIV/AIDS drug development and treatment
- Metabolism and Genetic Disorders
Agostino Gemelli University Polyclinic
2014-2023
Università Cattolica del Sacro Cuore
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2004-2023
Astellas Pharma (United Kingdom)
2017
Higher Institute on Territorial Systems for Innovation
2017
Catholic University of America
1998-2014
University of Foggia
2014
University of Milan
2004
Ospedale Maggiore
2004
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2004
DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C2Monitoring Versus Tacrolimus) was a 6-month, open-label, randomized, multicenter study which used American Diabetes Association/World Health Organization criteria to define glucose abnormalities. De novorenal transplant patients were randomized cyclosporine microemulsion (CsA-ME, using C2monitoring) or tacrolimus, with mycophenolic acid, steroids and basiliximab. The intent-to-treat population comprised 682 (336 CsA-ME, 346...
Short-term patient and graft outcomes continue to improve after kidney liver transplantation, with 1-year survival rates over 80%; however, improving longer-term remains a challenge. Improving the function of grafts health recipients would not only enhance quality length life, but also reduce need for retransplantation, thus increase number organs available transplant. The clinical transplant community needs identify manage those modifiable factors, decrease risk failure, outcomes.COMMIT was...
Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation.Methods In a multicenter noninferiority trial, we randomized 2037 de novo recipients to receive, in combination with induction therapy corticosteroids, everolimus reduced-exposure CNI (everolimus arm) or mycophenolic acid (MPA) standard-exposure (MPA arm). The primary end point was treated biopsy-proven acute rejection...
Current immunosuppressive regimens in renal transplantation typically include calcineurin inhibitors (CNIs) and corticosteroids, both of which have toxicities that can impair recipient allograft health. This 1-year, randomized, controlled, open-label, exploratory study assessed two belatacept-based compared to a tacrolimus (TAC)-based, steroid-avoiding regimen. Recipients living deceased donor allografts were randomized 1:1:1 receive belatacept-mycophenolate mofetil (MMF),...
TRANSFORM (TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen) was a 24-month, prospective, open-label trial in 2037 de novo renal transplant recipients randomized (1:1) within 24 hours of transplantation to receive everolimus (EVR) reduced-exposure calcineurin inhibitor (EVR + rCNI) or mycophenolate standard-exposure CNI. Consistent previously reported 12-month findings, noninferiority the EVR rCNI regimen for primary endpoint treated biopsy-proven acute rejection...
The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) using contemporary protocols in de novo kidney transplant recipients have not been compared detail.TRANSFORM was a randomized, international trial which patients were randomized to CNI (N = 1014) or mycophenolic acid (MPA) standard-exposure 1012), both induction and corticosteroids.Within the population (everolimus 1014, MPA adverse events suspected relation study drug occurred 62.9%...
Background— Patients undergoing revascularization procedures for peripheral vascular disease (PVD) have a greatly increased risk coronary artery (CAD) that is predicted only partly by clinical data and cardiovascular factors. We investigated whether the prognostic assessment in PVD patients could be improved preoperative measurements of C-reactive protein (CRP). Methods Results— assessed factors profiles, Eagle scores, CRP serum levels 51 with at Fontaine-Leriche stages II to IV without...
Tacrolimus, a cornerstone immunosuppressant, is widely available as twice-daily formulation (Tacrolimus BID). A once-daily prolonged-release QD) has been developed that may improve adherence and impart long-lasting graft protection. This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or BID. 6-week, open-label, randomized comparative was conducted centers Europe Australia. Eligible received PK profiles were obtained...
Background. In combination with everolimus (EVL), cyclosporine A (CsA) may be used at low exposure, so reducing the risk of renal dysfunction in transplant recipients (RTR). We evaluated whether higher exposure EVL could allow a further reduction CsA. Methods. De novo RTR were randomized to standard (C0 3–8 ng/mL) low-concentration CsA (C2 maintenance levels 350–500 ng/mL, group A) or 8–12 very 150–300 B). The primary endpoints 6-month creatinine clearance (CrCl) and biopsy-proven acute...
Italy was the first Western country to face COVID-19 pandemic. Here we report results of a national survey on kidney transplantation activity in February and March 2020, three-round Delphi consensus promoted by four scientific societies: Italian Society Organ Transplantation, Nephrology, Anesthesia Intensive Care, Group Antimicrobial Stewardship. All 41 transplant centers were invited express their opinion rounds along with group seven experts. The revealed that, starting from there decline...
Long-term use of corticosteroids is associated with considerable morbidity, including cardiovascular and metabolic adverse effects.This study evaluated the long-term efficacy safety two steroid-free regimens compared a triple immunosuppressive therapy in renal transplant recipients. This was 3-year follow-up to 6-month, open-label, randomized, multicenter study.Data from 3 years were available for 421 (93.3%) 451 patients original intent-to-treat population (143 tacrolimus/basiliximab...
Organ transplantation is an increasingly used medical procedure for treating otherwise fatal end-stage organ diseases, and a large number of anti-rejection drugs have been developed to prolong long-term survival both the individual transplanted organ. However, prolonged use immunosuppressive well known increase risk opportunistic particularly infections virus-related malignancies. Although transplant recipients experience nearly twofold elevated all types de novo cancers, persistent with...
Objectives Development of pharmaceutical agents in transplantation is currently limited by long waits for hard endpoints. We applied a validated integrative risk-prognostication system Box (iBox) as surrogate endpoint to the TRANSFORM Study, large randomised controlled trial, project individual patient long-term kidney allograft survival from 1 year 11 years after randomisation. Design Post-hoc analysis open-label trial. Setting Multicentre study including 186 centres 42 countries worldwide....